- Home
- ATEN vs AVBP Comparison
ATEN vs AVBP Comparison
Compare ATEN & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEN
- AVBP
- Stock Information
- Founded
- ATEN 2004
- AVBP 2021
- Country
- ATEN United States
- AVBP United States
- Employees
- ATEN N/A
- AVBP N/A
- Industry
- ATEN EDP Services
- AVBP
- Sector
- ATEN Technology
- AVBP
- Exchange
- ATEN Nasdaq
- AVBP NYSE
- Market Cap
- ATEN 1.3B
- AVBP 862.8M
- IPO Year
- ATEN 2014
- AVBP 2024
- Fundamental
- Price
- ATEN $19.48
- AVBP $20.82
- Analyst Decision
- ATEN Strong Buy
- AVBP Strong Buy
- Analyst Count
- ATEN 3
- AVBP 8
- Target Price
- ATEN $21.33
- AVBP $39.00
- AVG Volume (30 Days)
- ATEN 780.1K
- AVBP 481.2K
- Earning Date
- ATEN 08-05-2025
- AVBP 08-13-2025
- Dividend Yield
- ATEN 1.23%
- AVBP N/A
- EPS Growth
- ATEN 9.85
- AVBP N/A
- EPS
- ATEN 0.67
- AVBP N/A
- Revenue
- ATEN $267,158,000.00
- AVBP N/A
- Revenue This Year
- ATEN $9.40
- AVBP $85.82
- Revenue Next Year
- ATEN $7.66
- AVBP N/A
- P/E Ratio
- ATEN $29.14
- AVBP N/A
- Revenue Growth
- ATEN 4.90
- AVBP N/A
- 52 Week Low
- ATEN $12.27
- AVBP $15.47
- 52 Week High
- ATEN $21.90
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- ATEN 63.48
- AVBP 41.94
- Support Level
- ATEN $19.19
- AVBP $19.71
- Resistance Level
- ATEN $20.28
- AVBP $23.27
- Average True Range (ATR)
- ATEN 0.49
- AVBP 1.27
- MACD
- ATEN 0.06
- AVBP -0.44
- Stochastic Oscillator
- ATEN 70.80
- AVBP 18.36
About ATEN A10 Networks Inc.
A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.